Wednesday, September 16, 2020
Home Health Top Health News RDIF- Dr Reddy's tie up to manufacture coronavirus vaccine Sputnik V for...

RDIF- Dr Reddy’s tie up to manufacture coronavirus vaccine Sputnik V for India


RDIF- Dr Reddy's tie up to manufacture coronavirus vaccine Sputnik V for IndiaMUMBAI: The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund has tied up with India’s Dr. Reddy’s Laboratories to conduct the clinical trials and distribution of Sputnik V vaccine in India. As per the agreement RDIF will supply 100 million doses of the Covid-19 vaccine to Dr. Reddy’s said Kirill Dmitriev, CEO of RDIF to ET. The Sputnik V vaccine based on the adenoviral vector platform, Dmitriev said if the trials succeed the vaccines will be available in India as early as November this year.

RDIF is in talks with four other Indian manufacturers who will be producing these vaccines for India.

“The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations”, said a statement from the fund.

- Advertisement -

Adding that the platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”

“The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India,” said G V Prasad, CEO Dr Reddy’s in a statement.

A study published in Lancet in September this year showed that the vaccine was safe and produced cellular as well as antibody response to the vaccine based on the phase 1 and 2 data. The data from phase 3 studies is expected to be published by October-November. Responding to the criticism that Russia was jumping timelines to get its vaccine out without following all the protocols, Dmitriev told ET that the adenovirus platform is much safer than the mRNA vaccines which most western companies are manufacturing.

- Advertisement -

Adding that the platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences.”

- Advertisement -


Source
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Shama Sikander misses beaches and exotic places

Bollywood actor Shama Sikander is one water baby. She loves the beach and she has not been able to go to one for...

‘Air India earned over Rs 2550 crore revenue from Vande Bharat flights till Aug 31’

New Delhi: Air India earned a revenue of Rs 2556.60 crore from flights that have been operated under the Vande Bharat mission till...

Puducherry logs 518 new COVID-19 cases, 13 more die

Puducherry: Puducherry recorded 518 fresh cases of coronavirus and 13 related deaths on Wednesday, taking the aggregate to 21,111 in the union territory. With...

Record 82,961 recoveries in a day, a quarter from Maharashtra alone

New Delhi: A record 82,961 new COVID-19 recoveries were reported on Wednesday, almost a quarter of them from Maharashtra alone, pushing the overall...

Recent Comments